Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT ID: NCT06445088
Last Updated: 2024-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
908 participants
OBSERVATIONAL
2024-05-29
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
NCT06870435
Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs
NCT01972815
Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
NCT03087695
Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements
NCT05037357
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
NCT03973723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnosis cohort
The participant has signs or symptoms suggestive of nasopharyngeal carcinoma, or has a condition that needs to be differentiated from nasopharyngeal carcinoma
VCA-IgA, EBNA1-IgA, and EBV-DNA
Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
EBV C Promoter Methylation Detection in nasopharyngeal swab samples
Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VCA-IgA, EBNA1-IgA, and EBV-DNA
Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
EBV C Promoter Methylation Detection in nasopharyngeal swab samples
Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understand, sign, and date the informed consent document to participate in the study
* Display one or more symptoms or signs indicative of nasopharyngeal carcinoma
* Test positive for EBV antibodies or EBV DNA
* Be diagnosed with other head and neck carcinomas
* Be diagnosed with malignancies associated with EBV infection
* Require differential diagnosis from nasopharyngeal carcinoma during endoscopic or other imaging examinations
* Fulfill any additional conditions deemed appropriate by the investigator for inclusion in this study
Exclusion Criteria
* Experience relapse or metastasis of nasopharyngeal carcinoma following treatment
* Have unsuccessful nasopharyngeal swab collections
* Present any other conditions considered by the investigator as unsuitable for participation in this trial
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Cancer Hospital
OTHER_GOV
Wuzhou Red Cross Hospital
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hai-Qiang Mai,MD,PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hai-Qiang Mai
Role: STUDY_CHAIR
Sun Yat-sen University
Zhen-Zhou Xiao
Role: PRINCIPAL_INVESTIGATOR
Fujian Cancer Hospital
Min-Zhong Tang
Role: PRINCIPAL_INVESTIGATOR
Wuzhou Red Cross Hospital
Min-Yi Fu
Role: PRINCIPAL_INVESTIGATOR
Zhongshan People's Hospital, Guangdong, China
Zhe Zhang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Guangxi Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
ZhongShan City People's Hospital
Zhongshan, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YKP2023-02-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.